Making advances in first-line chronic lymphocytic leukemia treatment

Journal of Clinical Oncology

Volumn 30, Issue 26, 2012, Pages 3162-3164

  Wierda, William G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CD20 ANTIBODY; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; PENTOSTATIN; RITUXIMAB;

ADD ON THERAPY; ANEMIA; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; DRUG APPROVAL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELAPSE; REMISSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; NITROGEN MUSTARD COMPOUNDS;

EID: 84866539085     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.9738     Document Type: Editorial

References (22)

1. Knauf WU, Lissichkov T, Aldaoud A, et al: Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:4378-4384, 2009
2. Hallek M, Fischer K, Fingerle-Rowson G, et al: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 376:1164-1174, 2010
3. Robak T, Dmoszynska A, Solal-Céligny P, et al: Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 28:1756-1765, 2010
4. Fischer K, Cramer P, Busch R, et al: Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 29:3559-3566, 2011
5. Fischer K, Cramer P, Busch R, et al: Bendamustine combined with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 30:3209-3216, 2012
6. Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757, 2000
7. Eichhorst BF, Busch R, Hopfinger G, et al: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885-891, 2006 (Pubitemid 43156283)
8. Catovsky D, Richards S, Matutes E, et al: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 370:230-239, 2007 (Pubitemid 47069536)
9. Flinn IW, Neuberg DS, Grever MR, et al: Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 25:793-798, 2007 (Pubitemid 350002879)
10. Hillmen P, Skotnicki AB, Robak T, et al: Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616-5623, 2007
11. O'Brien S, Wierda WG, Faderl S, et al: FCR-3 as frontline therapy for patients with chronic lymphocytic leukemia (CLL). 47th ASH Annual Meeting and Exposition, Atlanta, GA, December 10-13, 2005 (abstr 2117)
12. Faderl S, Wierda W, O'Brien S, et al: Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 years. Leuk Res 34:284-288, 2010
13. Parikh SA, Keating MJ, O'Brien S, et al: Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood 118:2062-2068, 2011
14. Ferrajoli A, Faderl S, O'Brien S, et al: Experience with fludarabine, cyclophosphamide, rituximab (FCR) plus GM-CSF in frontline therapy for chronic lymphocytic leukemia (CLL). 50th ASH Annual Meeting and Exposition, San Francisco, CA, December 6-9, 2008 (abstr 3173)
15. Tam CS, O'Brien S, Wierda W, et al: Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112:975-980, 2008
16. Byrd JC, Peterson BL, Morrison VA, et al: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6-14, 2003 (Pubitemid 36025880)
17. Woyach JA, Ruppert AS, Heerema NA, et al: Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: Long-term follow-up of CALGB study 9712. J Clin Oncol 29:1349-1355, 2011
18. Kay NE, Geyer SM, Call TG, et al: Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109:405-411, 2007 (Pubitemid 46105933)
19. Keating MJ, O'Brien S, Albitar M, et al: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088, 2005 (Pubitemid 46211313)
20. Extermann M, Overcash J, Lyman GH, et al: Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16:1582-1587, 1998 (Pubitemid 28175784)
21. O'Brien S, Burger JA, Blum KA, et al: The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Follow-up of a phase Ib/II study. 53rd ASH Annual Meeting and Exposition, San Diego, CA, December 10-13, 2011 (abstr 983)
22. Furman RR, Byrd JC, Brown JR, et al: CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. 52nd ASH Annual Meeting and Exposition, Orlando, FL, December 4-7, 2010 (abstr 55)